MedTrace Logo

Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

NCT02159976 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2019-05-13

Study results available
· View outcomes & findings →

Summary

1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and to establish more effective first-line regimen for the eradication of Helicobacter pylori in Korea.
2. To evaluate the effect of H. pylori eradication therapy on the symptom improvement of functional dyspepsia

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Pantoprazole

Pantoprazole 40mg bid

DRUG

Amoxicillin

Amoxicillin 1000mg bid

DRUG

Clarithromycin

Clarithromycin 500mg bid

DRUG

Metronidazole

Metronidazole 500mg tid

DRUG

Tetracycline

Tetracycline 1000mg bid

DRUG

Bismuth

Bismuth 600mg bid

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    collaborator INDUSTRY

  • Chong Kun Dang Pharmaceutical

    collaborator INDUSTRY

  • HK inno.N Corporation

    collaborator INDUSTRY

  • Green Cross Corporation

    collaborator INDUSTRY

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-05-31
Completion
2016-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159976 on ClinicalTrials.gov